A novel siRNA, ARO-APOCIII, targeting apoC-III is currently in a late-stage clinical evaluation for lipid-lowering efficacy and overall safety profile with respect to thrombocytopenia [120]. Here, APOC3 is linked to Thrombocytopenia.